Literature DB >> 6431314

Bupropion in Parkinson's disease.

C G Goetz, C M Tanner, H L Klawans.   

Abstract

Bupropion is an antidepressant, thought to be an indirect dopaminergic agonist. No significant sympathomimetic, anti-cholinergic, or MAO inhibitor effects have been reported. We evaluated this drug in 20 patients with idiopathic Parkinson's disease. Parkinsonism lessened by at least 30% (Northwestern University Disability Scale or Modified New York University Parkinson's Disease Scale) in half the patients. Depression, present in 12 of 20, was alleviated in only 5. Bupropion is mildly efficacious in Parkinson's disease, although side effects were frequent and were dose-limiting in five patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431314     DOI: 10.1212/wnl.34.8.1092

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 3.  Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation.

Authors:  Andrew J Johnston; John Ascher; Robert Leadbetter; Virginia D Schmith; Dipak K Patel; Michael Durcan; Beth Bentley
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

5.  Treatment of Depression in the Patient with Parkinson's Disease.

Authors:  Tiffany W Chow; Jeffrey L Cummings
Journal:  Clin Geriatr       Date:  1998-10

Review 6.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 7.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

8.  Sleepiness and Unintended Sleep in Parkinson's Disease.

Authors:  David B. Rye
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 9.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 10.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.